Alcami has recently authored a white paper regarding the changing landscape in abuse-deterrent studies for controlled drugs.
Governmental and regulatory bodies, such as the U.S. Food and Drug Administration (FDA) and Department of Health and Human Services (HHS), have made significant investments towards the reduction of the misuse of prescription drugs.
Engineering abuse-deterrent properties into prescription forms of drugs with abuse potential has become a primary strategy for abuse prevention.
This white paper addresses:
- The cost of prescription drug abuse
- Overview of government action
- Abuse-deterrent strategies
- Abuse-deterrence study approaches